The Limitations of the Study and What's Coming Next

As a clinician, do you think we are ready to really start using the SAA tests in the clinical practice? I'm hopeful that in the future we'll have targeted therapies that aim specifically at snuclein pathology. And at that point, it'll be crucially important to know who has clinical Parkinson's disease syndrome based on snuculin pathology and who has an alternative pathology. The situation is really pretty analogous to what you're seeing in Alzheimer's now with the anti-amyloid therapies.